PERSONALIZED NUTRITION RECOMMENDATIONS FOR NORMALIZING BLOOD GLUCOSE LEVELS BASED ON MICROBIOME, MEDICAL AND PERSONAL RECORDS

Amir Golan¹, Lihi Segal², Rona Shacham³, ¹ Chief Commercial Officer, International, DayTwo, Adanim, Israel, ² CEO, DayTwo, Adanim, Israel, ³ Marketing and Business Development, DayTwo, Adanim, Israel

Investment Rational
DayTwo is the leading Microbiome-Based Precision Medicine company, developing personalized nutrition, diagnostic, and therapeutic solutions using artificial intelligence and machine learning on microbial genomics, human traits and disease.

- The company is a science driven company with top Microbiome scientists as co-founders and extensive research done at the Weizmann institute and the Mayo Clinic, backed by investment from J&J.

Business Strategy
- The company currently sells its first product (Personalized nutrition recommendations for normalizing blood glucose levels) both B2C & B2B2C
- Target audience is Diabetes and pre diabetes; Health/Athletes opportunistic basis
- Company launched a partnership with Clalit HMO, providing a joint service of personalized nutrition to 4.3M of Clalit patients
- Health Practitioners (Physicians, Dietitians, Diabetes Educators)
- 2019 focus on US (and IL) only.
- Long Term Strategy will expand current product to additional populations & base additional products on the microbiome platform.

Core Technology
- 5 years and $5M of investment by Weizmann scientists to develop the database and algorithm that predicts human metabolic phenotypes based on the microbiome.
- Microbiome can predict human metabolic phenotypes substantially more accurately than host genetics & is changeable unlike genes.
- This opens a huge opportunity for individualized treatments and diagnostics based on the microbiome.

Product Profile/Pipeline
- Current product: Personalized nutrition recommendations for normalizing blood glucose levels based on microbiome, medical and personal records
- Product continuously populates the biggest microbiome database in the world
- Product pipeline: Using AI on our unique microbiome dataset to provide Personalized nutritional and lifestyle recommendations for improving gut health
- Diagnostics based on microbiome
- Therapeutics based on microbiome

What's Next?
- Discussions with the FDA and CMS aiming to become Standard of Care for Diabetes
- New products based on the Microbiome as a Platform:
  - Nutrition recommendations for changing microbiome towards 'healthy gut'
  - Diagnostics Early indications in the microbiome for disease

Therapeutics - Identifying connections between microbiome and disease to support drug development